Group 1 - The core point of the article is that Kangzheng Pharmaceutical Holdings Limited plans to spin off its dermatology subsidiary, Demai Pharmaceutical, for an independent listing on the Hong Kong Stock Exchange through a distribution of shares to existing shareholders [1][2] - Demai Pharmaceutical focuses on the research and production of dermatological prescription drugs and skincare products, addressing common skin diseases such as psoriasis, vitiligo, atopic dermatitis, and acne, with a comprehensive solution for skin health [1] - The Chinese dermatology treatment and care market is rapidly growing, with a market size of 76.4 billion yuan in 2023 and an expected compound annual growth rate of 10.6% from 2023 to 2035 [1] Group 2 - Demai Pharmaceutical has a self-built commercialization team of over 650 professionals, with a sales network covering more than 10,000 hospitals and over 100,000 retail pharmacies, as well as major e-commerce platforms [2] - The projected revenue for Demai Pharmaceutical from 2022 to 2024 is 384 million yuan, 473 million yuan, and 618 million yuan, respectively, with a compound annual growth rate of 26.8% [2] - The spin-off is expected to benefit both the remaining group and the spun-off group by providing independent listing status, focused resources, enhanced business image, and improved employee stock incentive mechanisms [2]
康哲药业拟分拆德镁医药上市 瞄准皮肤健康市场